Nitric oxide and other reactive oxygen species generated by nitric-oxide synthases (NOS) modulate, among several other cellular responses, the production of eicosanoids and platelet aggregation. The roles of specific NOS in these two phenomena remain to be determined. Thus, the present study assessed whether inducible NOS (iNOS) and endothelial NOS (eNOS) modulate in a similar manner the production of eicosanoids and platelet aggregation. Mice knocked out for eNOS (eNOSϪ/Ϫ) or iNOS (iNOSϪ/Ϫ) and their wild-type (WT) congeners were used to analyze agonist-induced increases in plasma levels of eicosanoids as well as inhibition of platelet aggregation ex vivo. Systemically administered endothelin-1 (ET-1) triggered an increase in plasma levels of 6-keto prostaglandin F 1␣ (6-keto PGF 1␣ ) in WT and eNOSϪ/Ϫ but not in iNOSϪ/Ϫ mice. ET-1 (0.01-1 nmol/kg) also induced a dose-dependent inhibition of platelet aggregation in WT and eNOSϪ/Ϫ but not in iNOSϪ/Ϫ mice. Another agonist, bradykinin (10 nmol/kg), triggered the release of 6-keto PGF 1␣ and inhibited platelet aggregation in all strains of mice studied. In addition, ADP-induced platelet aggregation in vitro was similarly reduced by iloprost (100 nM) in iNOSϪ/Ϫ mice and WT congeners. In another series of experiments, ET-1 (0.1 nmol/kg) significantly increased 8-isoprostane plasma levels in WT but not in iNOSϪ/Ϫ mice. Finally, a 3-week treatment with anti-oxidants inhibited the capacity of ET-1 to significantly increase plasma 6-keto PGF 1␣ in WT mice. We show for the first time that iNOS is involved in the control of ET-1-induced prostacyclin release and related inhibition of platelet aggregation in the murine model.
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Arachidonic acid (AA) metabolites play important roles in thrombogenic/thrombolytic equilibrium. Among other mediators, eicosanoids such as prostacyclin (PGI 2 ) and thromboxane A 2 (TxA 2 ) have opposite effects on blood platelet functions with the former AA metabolite being an inhibitor and the latter a stimulant of platelet aggregation (Hamberg et al., 1975; Moncada et al., 1977) . TxA 2 is preferably released from blood platelets via cyclooxygenase-1 (COX-1) (albeit other cellular sources are described in the literature; Shen and Tai, 1998) , whereas prostacyclin is predominantly generated, in endothelial cells, via COX-2 (Norata et al., 2004) .
Another labile factor, NO, has also been shown to interfere with platelet function via cGMP-dependent mechanisms (Hogan et al., 1988) . NO can be generated from several cellular sources, via one or the other of three nitric-oxide synthases [neuronal (nNOS) , inducible (iNOS), endothelial (eNOS)].
A third endothelial-derived factor, endothelin-1 (ET-1) (Yanagisawa et al., 1988) , when injected systemically triggers indomethacin-sensitive inhibition of platelet aggregation ex vivo in both the rabbit and canine model (Filep et al., 1991; McMurdo et al., 1993) . More recently, in a mouse model, we reported that ET-1-induced antiplatelet properties are COX-2 and prostacyclin synthase-dependent, whereas the same effects afforded by bradykinin (BK) require the dual contributions of COX-2 and NOS (Labonté et al., 2001) . Finally, the antiplatelet properties of ET-1 in the mouse model were found to be solely dependent on ET B receptor activation (Labonté et al., 2001) .
Interestingly, an increasing body of evidence supports a regulation of eicosanoid production by nitric oxide or NO-derived molecular species, such as peroxinitrites and superoxide anions. Marnett and coworkers reported that targeted deletion of iNOS in the mouse causes a decrease in the urinary levels of prostaglandin E 2 and F2-isoprostane (Marnett et al., 2000) . The same study also reported that serum thromboxane B 2 (TxB 2 ) levels increased in iNOSϪ/Ϫ mice, suggesting that NO or other oxidant derivatives generated by the inducible isoform play significant roles in the genesis of AA metabolites. It has also been suggested that a constitutively expressed COX-2 in murine pulmonary tissues is required for protease-activated receptor-1 and protease-activated receptor-2-induced release of prostanoids (Kawabata et al., 2004) . Finally, mouse pulmonary alveolar epithelial cells release basally prostaglandin E 2 mainly via COX-2 activity (Lama et al., 2002) .
Thus, considering the above-mentioned studies, it is suggested that both physiologically functional iNOS and COX-2 are involved in the modulation of eicosanoid in the murine model. However, whether iNOS and eNOS act in a similar manner as modulators of AA metabolite production remains to be investigated. Therefore, the main goal of the present study was to compare the contribution of iNOS or eNOS in endothelin-1-induced production of PGI 2 , as well as in the anti-platelet properties of the 21 amino acid peptide in the mouse model. Furthermore, we attempted to correlate the PGI 2 and reactive oxygen species-releasing properties of ET-1 by two approaches, namely, via an antioxidant regime and by monitoring the production of 8-isoprostane as a marker of oxidative stress (Morrow et al., 1992; Janssen, 2001) . Overall, our results suggest a dynamic role for the inducible NOS in the prostacyclin-dependent modulation of platelet aggregation afforded by ET-1.
Materials and Methods

Animals
Wild-type (WT) mice (males and females, 16 -19 weeks old) C57BL/6J were purchased from Charles River (Montreal, QC, Canada). Breeding couples of homozygous iNOSϪ/Ϫ (Laubach et al., 1995) or eNOSϪ/Ϫ (Shesely et al., 1996) mice, with the same genetic background, were obtained from The Jackson Laboratory (Bar Harbor, ME). All animals were kept at constant room temperature (Ϯ23°C) and humidity (ϳ78%) under a controlled light/dark cycle (6:00 AM-6:00 PM). Animal care and experiments were approved by the Ethic Committee on Animal Research of the Université de Sherbrooke.
Blood Platelet Counts and Hematocrit Measurement
The mouse was restrained, and a distal 1-cm segment of tail was subsequently cut with a scalpel blade. A capillary was then filled with whole blood and transferred to a Unopette micro collection system (Fisher Scientific, Nepean, ON, Canada) for red blood cell lysis. Afterward, the lysate was carefully charged in a Neubauer hemocytometer for blood platelet counts (400ϫ magnification). The experiment was repeated at least twice for each animal.
For hematocrit monitoring, blood was collected in two separate heparinized microhematocrit capillary tubes and centrifuged in a microcapillary centrifuge model MB (International Equipment Co., Needham, MA).
Western Immunoblotting
WT, iNOSϪ/Ϫ or eNOSϪ/Ϫ mice were euthanized by cervical dislocation, and the heart, kidneys, lungs, and skeletal muscle of the left rear paw were removed.
Total proteins were extracted from organs and the protein concentration was assessed by the Bradford method. Samples were then applied on a 10% SDS-polyacrylamide gel (COX-1, 30 g; COX-2, 40 g; and PGI 2 S, 30 g) for protein separation. Proteins were then transferred on a polyvinylidene difluoride membrane (GE Healthcare, Baie D'Urfé, QC, Canada), which was blocked with 8% low fat dry milk. Thereafter, the membrane was incubated with the primary antibody and subsequently with horseradish-peroxidase-conjugated antibody. Primary antibodies for COX-1, COX-2, and PGI 2 S were purchased from Cayman Chemical (Hornby, ON, Canada); those for actin were from Sigma (Oakville, ON, Canada); and secondary antibodies have been obtained from GE Healthcare. The visualization of the immunoreactive proteins was performed using the chemiluminescent detection reagent ECL Plus from GE Healthcare.
Ex Vivo Platelet Aggregation Study
The animals were anesthetized with a mixture of ketamine (87 mg/kg)/xylazine (13 mg/kg) injected intramuscularly. The left jugular vein and the right carotid artery were cannulated using a polyethylene-10 catheter, the former serving for i.v. injection and the latter for blood pressure monitoring and blood sampling. Changes in mean arterial blood pressure (MAP) (expressed in ⌬ changes from basal values), under the anesthesia regime described above, were detected with a Statham pressure transducer (Statham Transducers Inc., Plato Rey, Puerto Rico) and recorded on a polygraph (model 79; Grass Instruments, Quincy, MA). After a 15-min stabilization, vehicle (phosphate-buffered saline; PBS), ET-1 (0.01-1 nmol/kg), or BK (10 nmol/kg) were administered i.v., and the responses were monitored for 5 min before blood sampling. The blood of two mice was pooled to obtain a volume of 1.5 ml in Eppendorf tubes with heparin (15 USP U/ml). The platelet-rich plasma and the platelet-poor plasma were obtained by centrifugation of the blood sample, and the platelet aggregation was monitored using an aggregometer model 490-2D (Chrono-Log Corporation, Havertown, PA), as described previously by our laboratory (Labonté et al., 2001 ). Induction of platelet aggregation was performed using ADP at a final concentration of 5 to 5.5 M in WT (C57BL/6J), eNOSϪ/Ϫ, and iNOSϪ/Ϫ mice to attain approximately 50% platelet aggregation. Separate groups of iNOSϪ/Ϫ and WT mice were treated with diethylenetriamine/NO (DETA/NO) (Sigma) 6 h before injection of vehicle (PBS) or ET-1 (0.1 nmol/kg). Mice were injected intraperitoneally with a dose of 51.7 mg/kg DETA/NO dissolved in saline 0.9%. This dose has been reported to be efficient to induce release of nitric oxide in the same strains of mice used in the present study (Cerwinka et al., 2002) . DETA/NO is a metabolically stable NO donor that scarcely increases plasma levels of oxidative product of NO (Yamamoto and Bing, 2000) .
In Vitro Platelet Aggregation Study
Blood was collected from WT, iNOSϪ/Ϫ, or eNOSϪ/Ϫ mice according to the protocol described in the previous section, with the exception that heparin was replaced by sodium citrate 3.8% (w/v) at a ratio 9:1 as anticoagulant. Platelet-rich plasma and platelet-poor plasma were then obtained as described in the above-mentioned section. After a 1-min stabilization period in the aggregometer to allow baseline setting, 100 nM iloprost (Cayman Chemical), a stable analog of prostacyclin, or vehicle (saline 0.9%) was administered 2 min before the addition of 10 M ADP.
Plasma Levels of Prostacyclin and Thromboxane A 2
Blood samples of 500 l [sodium citrate 0.35% (w/v)] were collected(SC110A SpeedVac Plus; ThermoSavant, Holbrook, NY) for final reconstitution in 150 l of enzyme immunoassay (EIA) kit buffer. The stable metabolites of either TxA 2 (TxB 2 ) or PGI 2 (6-keto prostaglandin F 1␣ ; 6-keto PGF 1␣ ) were quantified using respective EIA kits (Cayman Chemical). Unlike for TxB 2 monitoring, 6-keto PGF 1␣ was assayed without purification procedures.
Antioxidant Treatment in Wild-Type Mice
WT mice were treated with vehicle or a combination of a superoxide dismutase mimetic [tempol (4-hydroxy-tempo): 1 mM; Sigma] and a NADPH oxidase inhibitor [apocynin (4Ј-hydroxy-3Ј-methoxyacetophenone): 1.5 mM; Sigma] in drinking water for 3 weeks. These concentrations in drinking water have previously been shown to be efficient in reducing endothelin-1-induced superoxide anion production in rats (Elmarakby et al., 2005 ). Mice were subsequently tested for ET-1-induced increases of plasma level of proctacyclin as described above.
Monitoring of Total Plasma 8-Isoprostane
Plasma levels of total 8-isoprostane in WT or iNOS KO mice were assessed by an EIA kit from Cayman Chemical. The procedure for blood sampling was similar to that detailed above for prostacyclin and thromboxane A 2 monitoring following administration of PBS or ET-1 (0.1 nmol/kg). However, for the isoprostane protocol, 750-l blood volumes were collected to obtain 300 l of postcentrifugation plasma in which 0.005% (w/v) butylated hydroxytoluene was added before freezing. Sample purification was done following the recommendations of the manufacturer, using solid-phase extraction (SPE C18; 500 mg) cartridges (Waters, Mississauga, ON, Canada). Samples were eluted using 5 ml of ethyl acetate containing 1% methanol, evaporated under a gentle stream of nitrogen, and resuspended in 250 l of EIA buffer to be thereafter assayed using the EIA kit.
Monitoring of Plasma Free Nitrotyrosines
Basal-free nitrotyrosines, an indicator of peroxynitrite levels, were determined in plasma applied directly on a 96-well EIA kit (Cayman Chemical) (Feng et al., 2001 ).
Monitoring of Nitrates and Nitrites
Total nitrates/nitrites were measured using nitrates/nitrites colorimetric assay kits based on the Griess reaction (Cayman Chemical), in accordance with the manufacturer's recommendations.
Chemicals
ADP was obtained either from Chrono-Log Corporation or Sigma, and it was reconstituted in sterile irrigation grade 0.9% saline. ET-1 (Peptides International Inc., Louisville, KY) and BK (synthesized in our laboratory) were reconstituted and diluted with PBS.
Statistical Analyses
Data are expressed as mean Ϯ S.E.M. of n experiments. Statistical analyses were performed by Student's t test ‫,ءءء(‬ p Ͻ 0.001; ‫,ءء‬ p Ͻ 0.01, and ‫,ء‬ p Ͻ 0.05).
Results
Basal Parameters in WT, iNOS؊/؊, and eNOS؊/؊ Mice. Table 1 summarizes several basal parameters measured from plasma and blood of WT, iNOSϪ/Ϫ, and eNOSϪ/Ϫ mice. No differences were found in hematocrit in the three strains of mice, whereas blood platelet counts were similar in WT and iNOSϪ/Ϫ mice, yet they were reduced in eNOSϪ/Ϫ mice.
In contrast, reductions in plasma levels of nitrates/nitrites and free nitrotyrosines were found in iNOSϪ/Ϫ mice, but not eNOSϪ/Ϫ mice compared with WT littermates.
Finally, the knockout of either iNOS or eNOS genes in mice induced a significant increase in the basal plasma levels of 6-keto PGF 1␣ and TxB 2 , stable metabolites of PGI 2 and TxA 2 respectively, compared with WT mice.
Lack of Regulation of COX-1, COX-2, and PGI 2 Synthase Protein Levels by iNOS-and eNOS-Derived NO. In this series of experiments, we assessed whether an upregulation in COX-1, COX-2, or PGI 2 synthase protein levels was responsible for the increase in plasma levels of 6-keto PGF 1␣ and TxB 2 observed in iNOSϪ/Ϫ and eNOSϪ/Ϫ mice. We performed Western immunoblotting for each enzyme in cardiac or pulmonary homogenates derived from the three mouse strains.
Interestingly, the COX-2 protein was present in all organs studied (Fig. 1) in the three strains of mice. In addition, our results show that the protein levels of COX-1, COX-2, or PGI 2 synthase were not affected by the knockout of iNOS or eNOS genes in the heart, the lungs (Fig. 1) , the kidneys, and in the skeletal muscle (data not shown) of these mice. The Western immunoblots results also correlate with a lack of regulation of COX-1 and COX-2 mRNA expression in the four organs studied from iNOSϪ/Ϫ and eNOSϪ/Ϫ mice compared with WT congeners (data not shown).
ET-1 or BK-Dependent Release of Eicosanoid in WT, iNOS؊/؊, and eNOS؊/؊ Mice. In this series of experiments, we determined the impact of iNOS-or eNOS-derived NO on the ET-1-induced release of PGI 2 (6-keto PGF 1␣ ) in the circulation in vivo.
ET-1 (0.1 nmol/kg i.v.) induced a significant increase in the release of 6-keto PGF 1␣ in eNOSϪ/Ϫ or WT mice, but interestingly, not in iNOSϪ/Ϫ mice ( Fig. 2A) . In addition, ET-1 (0.1 nmol/kg i.v.) induces an increase in plasma levels of TxB 2 in both knockout animals, but not in their WT congeners ( Fig. 2A) .
To assess the specificity characteristics afforded by ET-1 in iNOSϪ/Ϫ mice, we investigated the release of eicosanoid induced by bradykinin. Intravenous injection of BK (10 nmol/kg) induced a marked increase in plasma levels of 6-keto PGF 1␣ in WT, iNOSϪ/Ϫ, and eNOSϪ/Ϫ mice, but it had no effect on plasma levels of TxB 2 in the three mouse strains studied (Fig. 2B) .
Endothelin-1-Induced Inhibition of ex Vivo Platelet Aggregation in WT, iNOS؊/؊, and eNOS؊/؊ Mice. We have previously shown that ET-1-induced inhibition of platelet aggregation is COX-2-dependent (Labonté et al., 2001) . In this series of experiments, the capacity of ET-1 to stimulate the release of prostacyclin ( Fig. 2A) was correlated with the antiplatelet properties of the peptide in iNOSϪ/Ϫ, eNOSϪ/Ϫ, and WT mice. Figure 3 represents a typical experiment showing the inability of ET-1 (0.1 nmol/kg) to reduce ADP-induced platelet aggregation ex vivo in iNOSϪ/Ϫ mice (Fig. 3C) , in contrast to the inhibitory response afforded by the same peptide in WT congeners (Fig. 3B) . Figure 4A shows the dose-dependent inhibition of ADPinduced platelet aggregation ex vivo by ET-1 (0.01 to 1 nmol/ kg) in WT and eNOSϪ/Ϫ mice, but not in iNOSϪ/Ϫ littermates. In a series of control experiments, BK (10 nmol/kg) induced a marked inhibition of ADP-induced platelet aggregation in WT, eNOSϪ/Ϫ, and iNOSϪ/Ϫ mice (Fig. 4A) . Figure 4B illustrates the pressor responses to ET-1 corresponding to each dose of the peptide used to assess the platelet inhibitory properties. Intravenously administered bradykinin triggered a hypotensive response in WT, iNOSϪ/Ϫ mice, and in eNOSϪ/Ϫ congeners, as reported previously (Brandes et al., 2000) in the latter strain (Fig. 4B) .
Effects of an Exogenously Administered NO Donor in iNOS؊/؊ Mice. In this series of experiments, we assessed whether a nitric oxide donor (e.g., DETA/NO) could restore the ET-1-induced inhibition of platelet aggregation in iNOSϪ/Ϫ mice. Thus, platelet aggregation following i.v. injection of vehicle (PBS) or ET-1 (0.1 nmol/kg) was monitored in WT and iNOSϪ/Ϫ mice treated previously with DETA/NO. This NO donor did not modify the ET-1-induced inhibition of platelet aggregation observed in WT mice (DETA/NO ϩ PBS, 52.8 Ϯ 0.80%; DETA/NO ϩ ET-1, 35 Ϯ 2.06%; p Ͻ 0.001 versus PBS injection), nor did it restore the inhibitory properties of the same peptide in iNOSϪ/Ϫ mice (DETA/NO ϩ PBS, 52.4 Ϯ 3.88%; DETA/NO ϩ ET-1, 49 Ϯ 2.85%; p Ͻ 0.01 versus ET-1 in WT mice) (n ϭ 4 -5). Finally, DETA/NO did not alter basal MAP in iNOSϪ/Ϫ or WT mice used in the present study (results not shown), in accordance with Cerwinka et al. (2002) .
ET-1-Dependent Release of Reactive Oxygen Species in the Mouse Model. In a separate series of experiments, ET-1 (0.1 nmol/kg) triggered a significant increase in 8-isoprostane plasma levels in WT mice (PBS, 179.11 Ϯ 20.55; ϩ ET-1, 267.63 Ϯ 13.51 pg/ml plasma; p Ͻ 0.01 versus PBS; n ϭ Table 1 ). 
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at ASPET Journals on July 13, 2017 jpet.aspetjournals.org 6 -7), but not in iNOSϪ/Ϫ mice (PBS, 277.85 Ϯ 30.52; ϩ ET-1, 351.31 Ϯ 23.58 pg/ml plasma; n ϭ 7). Worthy of notice, basal levels of 8-isoprostane were significantly higher in iNOSϪ/Ϫ mice compared with WT congeners (p Ͻ 0.05; n ϭ 6 -7).
Furthermore, a 3-week pretreatment with apocynin and tempol enhanced basal plasma levels of 6-keto PGF 1␣ in WT mice (220.28 Ϯ 30.90 pg/ml plasma; p Ͻ 0.05, n ϭ 6), compared with nontreated animals (Table 1) . Interestingly, ET-1 (0.1 nmol/kg) did not significantly increase plasma levels of 6-keto PGF 1␣ (275.96 Ϯ 19.14 pg/ml plasma; n ϭ 6), in tempol/apocynin-treated animals compared with vehicle-administered mice subjected to the same antioxidant regime.
In Vitro Inhibition of Platelet Aggregation by a Prostacyclin Analog. In this last series of experiments, we compared the in vitro responsiveness of platelets derived from WT, eNOSϪ/Ϫ, and iNOSϪ/Ϫ mice to a prostacyclin analog iloprost (100 nM). Figure 5 shows that iloprost equally reduced ADP-induced platelet aggregation in vitro in iNOSϪ/Ϫ and WT mice, whereas the inhibitory properties of the prostacyclin analog were potentiated significantly in platelets derived from eNOSϪ/Ϫ mice compared with those from WT mice.
Discussion
We have shown in the present study that intravascularly administered ET-1 increases circulating levels of prostacyclin in the mouse model, as shown previously in larger animal models (Filep et al., 1991; Mattera et al., 1994) . Furthermore, our data show that the inducible nitric-oxide synthase plays a pivotal role in the ET-1-induced release of prostacyclin. Indeed, in mice genetically repressed for the iNOS, the impaired PGI 2 -releasing capacity of ET-1 is correlated with the absence of antiaggregator properties ex vivo of the 21-amino acid peptide, whereas eNOS-deficient mice exhibit normal responses to ET-1. Interestingly, these iNOS-dependent properties seem to be restricted to the prostacyclinreleasing and antiplatelet effects of endothelin-1, because the same properties afforded by another vasoactive peptide, bradykinin, were ill-affected in iNOSϪ/Ϫ mice. Worthy of notice at ASPET Journals on July 13, 2017 jpet.aspetjournals.org Downloaded from also is that in the mouse model, both endothelin-1 and bradykinin are able to increase circulating levels of prostacyclin in eNOSϪ/Ϫ and only the latter peptide in iNOSϪ/Ϫ mice, irrespective of the enhanced basal levels of eicosanoids. Thus, distinct mechanisms seem to be involved in the modulation by NO and/or reactive oxygen species (ROS) of basal eicosanoid production versus agonist-induced PGI 2 release and related antiplatelet effects.
The ET-1-specific intracellular mechanisms involved in the iNOS-PGI 2 cross talk, proposed in the present study, have yet to be fully elucidated. Interestingly, it has been reported that ET-1 stimulates the production of superoxide anions (O 2 . ) in vascular cells as well as in carotid arteries in the rat model (Li et al., 2003; Pollock and Pollock, 2005) . Furthermore, O 2 . regulates COX-2 by increasing the expression of the enzyme (von Knethen et al., 1999; Martinez et al., 2000) , whereas the iNOS-derived NO enhances the activity of the enzyme via cGMP-independent pathway mechanisms (Shinmura et al., 2002) . Our results show that plasma levels of 8-isoprostane were significantly enhanced by ET-1 in WT, but not in iNOSϪ/Ϫ mice, irrespective of enhanced basal levels of the oxidated eicosanoid reported here in the latter strain, as also previously shown in eNOSϪ/Ϫ mice (Shi et al., 2002) . Furthermore, an antioxidant regime with tempol and apocynin (Elmarakby et al., 2005) reduced the capacity of ET-1 to stimulate plasma increase of 6-keto PGF 1␣ in WT congeners. These two series of results suggest that ET-1 enhances the production of ROS in the wild-type mouse, as shown previously in the rat model (Elmarakby et al., 2005) . Our data also highlight the contribution of ROS in the ET-1-induced production of PGI 2 in WT mice. In the present study, protein levels of COX-2 and prostacyclin synthase were also shown to be unaltered by the repression of the inducible NOS gene. Considering that we have previously shown that ET-1-dependent inhibition of ADP-induced platelet aggregation is fully reversed by either COX-2 (NS-398) or prostacyclin synthase (tranylcypromine) inhibitors (Labonté et al., 2001) , we suggest that the lack of PGI 2 -releasing properties of ET-1 in iNOSϪ/Ϫ mice is caused by a reduction in COX-2 or PGI 2 synthase activity per se rather than by changes in protein levels of these two enzymes. This state of events would be due to a diminished capacity of the 21-amino acid peptide to generate ROS, such as O 2 . in iNOSϪ/Ϫ mice. It is established that NO, generated by the inducible NOS, reacts with O 2 . to produce peroxynitrites, a known signaling molecule (Faraci, 2006) . The predominant role of ROS rather than NO itself was also confirmed by the fact that DETA/NO did not correct the repression of ET-1-induced inhibition of platelet aggregation ex vivo observed in iNOSϪ/Ϫ mice. Finally, the prostacyclin receptor agonist iloprost (Armstrong et al., 1989; Costantini et al., 1990 ) reversed ADPinduced platelet aggregation in vitro in WT, iNOSϪ/Ϫ, and eNOSϪ/Ϫ mice. This last result suggests that cAMP-dependent inhibition of aggregation following direct PGI 2 receptor stimulation (Krause and Krais, 1986) in mouse platelets is left intact in iNOSϪ/Ϫ or eNOSϪ/Ϫ mice compared with WT congeners. This last series of experiments allows us to confirm that the repression of the ET-1-induced inhibition of platelet aggregation in iNOSϪ/Ϫ mice can clearly be associated with the lost capacity of the peptide to increase plasma PGI 2 rather than a modulation of platelet reactivity to the stimulation of prostacyclin receptors.
On a physiological point of view, several studies have recently confirmed the pivotal role of COX-2 in the production of PGI 2 in humans (Stichtenoth et al., 2005; Grosser, 2006) . Likewise, the ex vivo platelet inhibition afforded by endothelin-1 in the murine model has been previously shown, by our group, to be also dependent on COX-2-derived prostacyclin synthesis (Labonté et al., 2001 ). Whether these COX-2-dependent antiplatelet responses occurring in the mouse model can be translated to human needs to be confirmed. A recent review (Flavahan, 2007) , for example, exerts some caution on this latter issue by arguing for a predominant contribution of the COX-1 isoform in the production of prostacyclin in human subjects.
Worthy of notice, the potential role of the neuronal isoform of NOS in our ex vivo platelet aggregation model has not been investigated. Among other studies, the platelet-derived growth factor has been shown to up-regulate nNOS expression in isolated blood vessels of WT, eNOSϪ/Ϫ, and iNOSϪ/Ϫ but not nNOSϪ/Ϫ mice (Nakata et al., 2005) . In addition, neuronal NOS-dependent compensatory mechanisms on coronary blood flow in eNOSϪ/Ϫ mice have also been reported (Huang et al., 2002) . However, this type of nNOS-dependent compensation in iNOSϪ/Ϫ mice is, to our knowledge, yet to be explored.
In summary, our results support the concept that the inducible NOS plays a pivotal role in the prostacyclin-releasing and antiplatelet properties of endothelin-1 in the mouse. Furthermore, our study provides new insight on the putative cross talk between the inducible NOS and cyclooxygenasedependent mechanisms in cardiovascular homeostasis. 
